

---

## FUTURE PLANS AND USE OF PROCEEDS

---

### FUTURE PLANS

See “Business — Our Strategies” in this prospectus for a detailed description of our future plans.

### USE OF PROCEEDS

Assuming an Offer Price of HK\$21.00 per H Share, being the mid-point of the indicative Offer Price range stated in this prospectus, and assuming the Over-allotment Option is not exercised, we currently intend to use such net proceeds from the Global Offering as follows:

- approximately 41.7% of the net proceeds, or approximately HK\$656.2 million, is expected to be used for investment in two imaging diagnostic and therapeutic radiopharmaceuticals manufacturing and research and development bases in Xianghe, Hebei province and Chengdu, Sichuan province to enhance our manufacturing and research and development capabilities. See “Business — Expansion Plan” for further details;
- approximately 4.7% of the net proceeds, or approximately HK\$74.0 million, is expected to be used for establishment of four manufacturing and distribution subsidiaries to primarily produce and distribute technetium-99m-labeled injections and fluorine-18-FDG injection in China. See “Business — Expansion Plan” for further details;
- approximately 5.9% of the net proceeds, or approximately HK\$92.8 million, is expected to be used for the establishment of new production facilities in Shenzhen, Guangdong province and Tongcheng, Anhui province to expand our manufacturing capacity of UBT kits and analyzers. See “Business — Expansion Plan” for further details;
- approximately 17.7% of the net proceeds, or approximately HK\$278.5 million, is expected to be used for investment in the research and development of various imaging diagnostic and therapeutic radiopharmaceuticals, raw materials of radioactive source product, medical radioisotopes, and UBT products and related raw materials. See “Business — Research and Development” for further details;
- approximately 20.0% of the net proceeds, or approximately HK\$314.7 million, is expected to be used for selective acquisitions. Please see “Business — Our Strategies” for the selection criteria of acquisition targets;
- approximately 10.0% of the net proceeds, or approximately HK\$157.4 million, is expected to be used for working capital and general corporate purposes.

We estimate that we will receive from the Global Offering net proceeds, after deducting the underwriting fees and estimated expenses payable by us in connection with the Global Offering, in the amount as set forth in the following table:

	Based on the low-end of the proposed Offer Price range of HK\$17.80	Based on the mid-end of the proposed Offer Price range of HK\$21.00	Based on the high-end of the proposed Offer Price range of HK\$24.20
Assuming the Over-allotment Option is not exercised . . . . .	Approximately HK\$1,317.7 million	Approximately HK\$1,573.6 million	Approximately HK\$1,829.5 million
Assuming the Over-allotment Option is exercised in full . . . . .	Approximately HK\$1,531.3 million	Approximately HK\$1,825.5 million	Approximately HK\$2,119.8 million

To the extent that the net proceeds from the Global Offering (including the net proceeds from the exercise of the Over-allotment Option) are either more or less than expected, we will adjust our allocation of the net proceeds for the above purposes on a pro rata basis.

---

## **FUTURE PLANS AND USE OF PROCEEDS**

---

To the extent that the net proceeds from the Global Offering are not immediately used for the above purposes, we currently intend to deposit such net proceeds into short-term interest-bearing accounts, such as savings accounts or money market funds, with licensed commercial banks or other authorized financial institutions.